Premium
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table
Author(s) -
Grosset Katherine,
Needleman Fiona,
Macphee Graeme,
Grosset Donald
Publication year - 2004
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20210
Subject(s) - agonist , dopamine , dopamine agonist , medicine , parkinson's disease , pharmacology , anesthesia , dopaminergic , disease , receptor
Of 99 patients on ergot‐derived dopamine agonists informed about possible long‐term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population. © 2004 Movement Disorder Society